FDA Experts Weigh In On Incannex’s CannQuit-O With Feedback On CBD As Treatment For Opioid Use Disorder – Incannex Healthcare (NASDAQ:IXHL)
Medical Marijuana Program Connection
MAY 7, 2024
IXHL, a cannabinoid and psychedelic medicine biotechnology company, announced the successful completion of a pre-investigational new drug meeting with the U.S. Incannex Healthcare Inc. Food and Drug Administration (FDA) regarding the development of CannQuit-O for the treatment of opioid use disorder (OUD).
40 
Let's personalize your content